Adaptimmune Shares Encouraging Data From Solid Tumor Trial

Adaptimmune Therapeutics plc ADAP has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8.
ADP-A2M4CD8 is a next-generation T-cell therapy engineered to target MAGE-A4 positive tumors and to express a CD8α co-receptor.
Data will be presented at the upcoming European Society for Medical Oncology (ESMO) annual meeting.
Initial efficacy and durability data showed encouraging responses across five different solid tumors, with an overall response rate of 36% and a disease control rate was 86%
Complete response reported in a patient with ovarian cancer, which remains ongoing at 6 months post‑infusion.
Initial durability is encouraging. As of the data cut-off, 11 patients remain on study. Of the 8 responders, 5 remain in response, with some remaining progression-free over 24 weeks.
Data confirmed preclinical observations that the enhanced TCR interaction in ADP-A2M4CD8 results in a more potent product.
Eighteen (72%) patients experienced cytokine release syndrome (CRS) related to T-cell infusion, most of which were moderate.
Related Content: Adaptimmune Inks Cancer Deal With Genentech.
Price Action: ADAP stock is up 3.36% at $6.04 during the market session on the last check Monday.